Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Process scale considerations in evaluation studies and scale-up

J K Walter1, W Werz, W Berthold

  • 1Department Biotech Production, Dr. Karl Thomae GmbH, Biberach, Germany.

Developments in Biological Standardization
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When physicians forego the doctor-patient relationship, should they elect to self-prescribe or curbside? An empirical and ethical analysis.

Journal of medical ethics·2009
Same author

Redox-sensitivity of the dimerization of occludin.

Cellular and molecular life sciences : CMLS·2009
Same author

Dynamics of electronic transfer processes at metal/insulator interfaces.

Chemical reviews·2006
Same author

Time-resolved two-photon photoemission of buried interface states in Ar/Cu(100).

Physical review letters·2005
Same author

Effect of an atomically thin dielectric film on the surface electron dynamics: image-potential states in the Ar/Cu(100) system.

Physical review letters·2002
Same author

Momentum-resolved lifetimes of image-potential States on cu(100).

Physical review letters·2002
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Demonstrating viral clearance in biopharmaceutical downstream processing is crucial for drug safety. Studies must validate methods for removing or inactivating potential viral contamination from cell cultures and antibodies.

Area of Science:

  • Biopharmaceutical Manufacturing
  • Virology
  • Process Validation

Background:

  • Recombinant DNA-derived proteins and monoclonal antibodies (MAbs) carry a risk of viral contamination from cell cultures.
  • Adventitious viruses and retroviral particles pose a significant safety concern in biopharmaceutical production.
  • Downstream processing must effectively reduce or eliminate potential viral loads.

Purpose of the Study:

  • To examine the scale and requirements of validation studies for viral clearance in biopharmaceutical downstream processing.
  • To highlight the importance of designing downstream processes with both viral clearance and validation capabilities.
  • To ensure the safety of biopharmaceutical products through rigorous viral clearance validation.

Main Methods:

  • Focus on the scale of validation studies for viral clearance.

Related Experiment Videos

  • Analysis of downstream processing strategies for virus removal and inactivation.
  • Consideration of process design for both clearance and validation.

    • Main Results:

    • Viral clearance validation is essential for ensuring drug safety.
    • Downstream processes must be designed to significantly reduce viral load.
    • Both virus removal and inactivation methods are critical components.

    Conclusions:

    • Effective viral clearance is a non-negotiable aspect of biopharmaceutical manufacturing.
    • Validation studies must be robust to confirm the safety of therapeutic products.
    • Process design must integrate viral clearance and validation strategies from the outset.